Piper Sandler initiated coverage of Crinetics Pharmaceuticals with an Overweight rating and $56 price target. The analyst believes disease acromegaly could be a potential blockbuster market opportunity for the company. Upcoming pivotal trials of PATHFNDR in acromegaly carry low biological, regulatory and clinical risk, the analyst tells investors in a research note. The firm says acromegaly represents a large market opportunity with potential peak sales of over $2B.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRNX:
- 3 Best Stocks to Buy Now, 4/24/2023, According to Top Analysts
- Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Baird starts Crinetics with Outperform on ‘undervalued asset’
- Crinetics initiated with an Outperform at Baird
- Crinetics initiated with an Outperform at LifeSci Capital
